Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?

Mednet Member

Medical Oncology · Ellison Institute, LLC

The OlympiA study resulted in a statistically significant iDFS and DDFS benefit with adjuvant olaparib vs placebo in high-risk, HER2-negative patients with gBRCA mutation. Given the notable improvement in outcomes, it is imperative that every potentially eligible patient be considered for adjuvant o...